Makoto Samukawa

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text

Predicting Outcome in Guillain-Barré Syndrome

Alex Y. Doets, Hester F. Lingsma, Christa Walgaard et al. · Neurology · 2021 · 61 citations · Full text

Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis

Akiyuki Uzawa, Shigeaki Suzuki, Satoshi Kuwabara et al. · Journal of Neurology Neurosurgery & Psychiatry · 2023 · 48 citations